Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER)-Reference-Cited by-同舟云学术

Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER)

Published:2022-04-22 Issue: Volume: Page:1-12
ISSN:2376-0540
Container-title:Journal of Managed Care & Specialty Pharmacy
language:en
Short-container-title:JMCP

Author:

Ambrosini Anna¹,Estemalik Emad²,Pascual Julio³,Rettiganti Mallikarjuna⁴,Stroud Chad⁴,Day Kathleen⁴,Ford Janet⁴

Affiliation:

1. Headache Clinic, IRCCS Neuromed, Pozzilli, IS, Italy.

2. Cleveland Clinic Lerner College of Medicine, Cleveland, OH.

3. University Hospital Marqués de Valdecilla, University of Cantabria and IDIVAL, Santander, Spain.

4. Eli Lilly and Company, Indianapolis, IN.

Publisher

Academy of Managed Care Pharmacy

Subject

Health Policy,Pharmaceutical Science,Pharmacy

Reference39 articles.

1. Migraine

2. Impact of NSAID and Triptan Use on Developing Chronic Migraine: Results From the American Migraine Prevalence and Prevention (AMPP) Study

3. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: A systematic review

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials;Headache: The Journal of Head and Face Pain;2024-04-18

2. Migraine treatment: quo vadis? Real-world data study (2015–2022) in Spain;BMC Neurology;2024-04-02

3. Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response;Pain and Therapy;2024-03-12

4. Monoclonal antibodies targeting the calcitonin gene-related peptide pathway improve the effectiveness of acute medication—a real-world study;Neurological Sciences;2024-02-10

5. Long-Term Effectiveness of Galcanezumab in the Prevention of Migraine: An Italian Retrospective Analysis (REALITY);Neurology and Therapy;2024-02-08